So, we speculated that CDK1 inhibitors can reduce the expression of the CDK1 gene in Tprolif cells, promote the proliferation of Tprolif cells, and strengthen the immunosuppressive effect of immune cells on hepatocellular carcinoma. This evidence concerns the gene CDK1 and hepatocellular carcinoma.